{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:27:22Z","timestamp":1783459642092,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejphar.2023.175727","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T23:38:40Z","timestamp":1681515520000},"page":"175727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Apelin\/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential"],"prefix":"10.1016","volume":"949","author":[{"given":"Bo","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Ru","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xue","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175727_bib1","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1111\/febs.16048","article-title":"Critical APJ receptor residues in extracellular domains that influence effector selectivity","volume":"288","author":"Ashokan","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2023.175727_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132898","article-title":"Cardiovascular response to small-molecule APJ activation","volume":"5","author":"Ason","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejphar.2023.175727_bib3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.5603\/KP.a2017.0022","article-title":"Post-infarct treatment with [Pyr1]apelin-13 exerts anti-remodelling and anti-apoptotic effects in rats' hearts","volume":"75","author":"Azizi","year":"2017","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.ejphar.2023.175727_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep16104","article-title":"Apelin regulates FoxO3 translocation to mediate cardioprotective responses to myocardial injury and obesity","volume":"5","author":"Boal","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175727_bib5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/HYPERTENSIONAHA.114.05099","article-title":"Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist","volume":"65","author":"Brame","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2023.175727_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-011-9507-9","article-title":"Apelin, diabetes, and obesity","volume":"40","author":"Castan-Laurell","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2023.175727_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111278","article-title":"The therapeutic potentials of apelin in obesity-associated diseases","volume":"529","author":"Castan-Laurell","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175727_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.yjmcc.2013.07.002","article-title":"Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction","volume":"63","author":"Ceylan-Isik","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/01.CIR.0000091235.94914.75","article-title":"Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction","volume":"108","author":"Chen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2023.175727_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.33549\/physiolres.934488","article-title":"Apelin-13 regulates angiotensin ii-induced Cx43 downregulation and autophagy via the AMPK\/mTOR signaling pathway in HL-1 cells","volume":"69","author":"Chen","year":"2020","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ejphar.2023.175727_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170697","article-title":"Apelin pathway in cardiovascular, kidney, and metabolic diseases: therapeutic role of apelin analogs and apelin receptor agonists","volume":"147","author":"de Oliveira","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2023.175727_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming growth factor (TGF)-beta signaling in cardiac remodeling","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13543776.2020.1731473","article-title":"A patent review of apelin receptor (APJR) modulators (2014-2019)","volume":"30","author":"Fischer","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejphar.2023.175727_bib14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.febslet.2010.04.025","article-title":"Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy","volume":"584","author":"Foussal","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2023.175727_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007351","article-title":"In vitro and in vivo evaluation of a small-molecule APJ (apelin receptor) agonist, BMS-986224, as a Potential Treatment for Heart Failure","volume":"14","author":"Gargalovic","year":"2021","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.ejphar.2023.175727_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1096\/fj.14-256339","article-title":"New structural insights into the apelin receptor: identification of key residues for apelin binding","volume":"29","author":"Gerbier","year":"2015","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2023.175727_bib17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1021\/acs.oprd.1c00088","article-title":"Development of two synthetic approaches to an APJ receptor agonist containing a tetra-ortho-substituted biaryl pyridone","volume":"26","author":"Goldfogel","year":"2021","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejphar.2023.175727_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116748","article-title":"Resveratrol prevents chronic intermittent hypoxia-induced cardiac hypertrophy by targeting the PI3K\/AKT\/mTOR pathway","volume":"233","author":"Guan","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2023.175727_bib19","first-page":"547","article-title":"Evaluation of novel cyclic analogues of apelin","volume":"22","author":"Hamada","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ymgme.2016.07.012","article-title":"Apelin\/APJ system as a therapeutic target in diabetes and its complications","volume":"119","author":"Hu","year":"2016","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2023.175727_bib21","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1096\/fj.09-140715","article-title":"Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist","volume":"24","author":"Iturrioz","year":"2010","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejphar.2023.175727_bib22","doi-asserted-by":"crossref","first-page":"32627","DOI":"10.1074\/jbc.M110.127167","article-title":"By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization","volume":"285","author":"Iturrioz","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib23","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/cmdc.201600307","article-title":"Development of potent and metabolically stable APJ ligands with high therapeutic potential","volume":"11","author":"Juhl","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2023.175727_bib24","doi-asserted-by":"crossref","first-page":"18465","DOI":"10.1074\/jbc.M110.200022","article-title":"Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase\/mammalian target of rapamycin (AMPK\/mTOR) and c-Jun N-terminal kinase\/insulin receptor substrate 1 (JNK\/IRS1) pathways","volume":"286","author":"Kang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib25","series-title":"Probe Reports from the NIH Molecular Libraries Program","author":"Khan","year":"2010"},{"key":"10.1016\/j.ejphar.2023.175727_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/folmed-2017-0066","article-title":"Relations of apelin with cardiac remodeling in patients with hypertension and type 2 diabetes","volume":"60","author":"Koval","year":"2018","journal-title":"Folia Med. (Plovdiv)"},{"key":"10.1016\/j.ejphar.2023.175727_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.peptides.2018.04.011","article-title":"Apelin and Elabela\/Toddler; double ligands for APJ\/Apelin receptor in heart development, physiology, and pathology","volume":"111","author":"Kuba","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2023.175727_bib28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.111.172700","article-title":"New take on the role of angiotensin II in cardiac hypertrophy and fibrosis","volume":"57","author":"Kurdi","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2023.175727_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/bi801864b","article-title":"Structural insight into G-protein coupled receptor binding by apelin","volume":"48","author":"Langelaan","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2023.175727_bib30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbamem.2013.02.005","article-title":"Structural features of the apelin receptor N-terminal tail and first transmembrane segment implicated in ligand binding and receptor trafficking","volume":"1828","author":"Langelaan","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2023.175727_bib31","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.3390\/molecules25225279","article-title":"Novel therapeutic effects of pterosin B on Ang II-Induced cardiomyocyte hypertrophy","volume":"25","author":"Lee","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2023.175727_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jcmm.16052","article-title":"Elabela may regulate SIRT3-mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic-induced myocardial injury","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/abbs\/gmw025","article-title":"The role of autophagy in cardiac hypertrophy","volume":"48","author":"Li","year":"2016","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejphar.2023.175727_bib34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/abbs\/gmx098","article-title":"Elabela-APJ axis: a novel therapy target for cardiovascular diseases","volume":"49","author":"Li","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejphar.2023.175727_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7150\/ijbs.11883","article-title":"Functions of autophagy in pathological cardiac hypertrophy","volume":"11","author":"Li","year":"2015","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2023.175727_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0034-1395585","article-title":"Regulation of mTOR pathway in exercise-induced cardiac hypertrophy","volume":"36","author":"Liao","year":"2015","journal-title":"Int. J. Sports Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/abbs\/gmq035","article-title":"PI3K\/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13","volume":"42","author":"Liu","year":"2010","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejphar.2023.175727_bib38","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jacbts.2019.05.011","article-title":"Epigenetics in cardiac hypertrophy and heart failure","volume":"4","author":"Liu","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ejphar.2023.175727_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijcard.2016.11.215","article-title":"Apelin\/APJ system: a bifunctional target for cardiac hypertrophy","volume":"230","author":"Lu","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3892\/br.2016.749","article-title":"Resistin-induced cardiomyocyte hypertrophy is inhibited by apelin through the inactivation of extracellular signal-regulated kinase signaling pathway in H9c2 embryonic rat cardiomyocytes","volume":"5","author":"Luo","year":"2016","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.ejphar.2023.175727_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/8866725","article-title":"Relationship between apelin\/APJ signaling, oxidative stress, and diseases","volume":"2021","author":"Lv","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2023.175727_bib42","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10741-020-09957-5","article-title":"The Elabela-APJ axis: a promising therapeutic target for heart failure","volume":"26","author":"Ma","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2023.175727_bib43","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cmdc.201100069","article-title":"Discovery of a competitive apelin receptor (APJ) antagonist","volume":"6","author":"Macaluso","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2023.175727_bib44","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.bmcl.2012.08.105","article-title":"Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor","volume":"22","author":"Maloney","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2023.175727_bib45","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1021\/jm401789v","article-title":"Structure-activity relationship studies toward the discovery of selective apelin receptor agonists","volume":"57","author":"Margathe","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib46","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/emboj.2008.233","article-title":"Gq-coupled receptors as mechanosensors mediating myogenic vasoconstriction","volume":"27","author":"Mederos y Schnitzler","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2023.175727_bib47","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1046\/j.1471-4159.2003.01587.x","article-title":"Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin","volume":"84","author":"Medhurst","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2023.175727_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cmdc.201100492","article-title":"Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability","volume":"7","author":"Murza","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2023.175727_bib49","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1021\/acs.jmedchem.5b01549","article-title":"Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions","volume":"59","author":"Murza","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116789","article-title":"Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin receptor","volume":"66","author":"Narayanan","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib51","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1016\/j.bmc.2016.06.018","article-title":"Discovery of a novel small molecule agonist scaffold for the APJ receptor","volume":"24","author":"Narayanan","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115237","article-title":"Identification of potent pyrazole based APELIN receptor (APJ) agonists","volume":"28","author":"Narayanan","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib53","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/JOE-13-0227","article-title":"The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis","volume":"219","author":"O'Carroll","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2023.175727_bib54","doi-asserted-by":"crossref","first-page":"H348","DOI":"10.1152\/ajpheart.00693.2017","article-title":"Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition","volume":"315","author":"Parikh","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/science.1248636","article-title":"Toddler: an embryonic signal that promotes cell movement via Apelin receptors","volume":"343","author":"Pauli","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2023.175727_bib56","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/eurheartj\/ehr389","article-title":"Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1","volume":"33","author":"Pchejetski","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2023.175727_bib57","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1021\/acsmedchemlett.1c00385","article-title":"Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as potent and orally active APJ receptor agonists","volume":"12","author":"Pi","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2023.175727_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000769","article-title":"Beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress","volume":"3","author":"Rakesh","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejphar.2023.175727_bib59","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10989-018-9707-8","article-title":"ELABELA (ELA) peptide exerts cardioprotection against myocardial infarction by targeting oxidative stress and the improvement of heart function","volume":"25","author":"Rakhshan","year":"2018","journal-title":"Int. J. Pept. Res. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175727_bib60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.freeradbiomed.2021.02.040","article-title":"Oxidative stress in cardiac hypertrophy: from molecular mechanisms to novel therapeutic targets","volume":"166","author":"Ramachandra","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127499","article-title":"Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation","volume":"30","author":"Reed","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2023.175727_bib62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2016.07.018","article-title":"Cardiac action of the first G protein biased small molecule apelin agonist","volume":"116","author":"Read","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175727_bib63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/pr.119.017533","article-title":"International union of basic and clinical pharmacology. CVII. structure and pharmacology of the apelin receptor with a recommendation that Elabela\/Toddler is a second endogenous peptide ligand","volume":"71","author":"Read","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2023.175727_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/ijms20020239","article-title":"Loss of apelin augments angiotensin II-induced cardiac dysfunction and pathological remodeling","volume":"20","author":"Sato","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175727_bib65","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/cvr\/cvx061","article-title":"ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage","volume":"113","author":"Sato","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2023.175727_bib66","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1172\/JCI69608","article-title":"Apelin is a positive regulator of ACE2 in failing hearts","volume":"123","author":"Sato","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.175727_bib67","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/14779072.2014.911661","article-title":"Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy","volume":"12","author":"Scimia","year":"2014","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.ejphar.2023.175727_bib68","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nature11263","article-title":"APJ acts as a dual receptor in cardiac hypertrophy","volume":"488","author":"Scimia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.175727_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/hrt.2005.068270","article-title":"Oxidative stress and redox signalling in cardiac hypertrophy and heart failure","volume":"93","author":"Seddon","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2023.175727_bib70","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fphys.2020.00181","article-title":"Stretch-induced biased signaling in angiotensin II type 1 and apelin receptors for the mediation of cardiac contractility and hypertrophy","volume":"11","author":"Seo","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib71","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/cphy.c170028","article-title":"Apelinergic system structure and function","volume":"8","author":"Shin","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib73","first-page":"209","article-title":"Angiotensin (1-7) and Apelin co-therapy: new strategy for heart failure treatment of rats","volume":"23","author":"Soltani Hekmat","year":"2020","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.freeradbiomed.2019.01.052","article-title":"Ferritinophagy activation and sideroflexin1-dependent mitochondria iron overload is involved in apelin-13-induced cardiomyocytes hypertrophy","volume":"134","author":"Tang","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128325","article-title":"Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1H)-one APJ receptor agonists","volume":"50","author":"Tora","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2023.175727_bib76","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/acs.jmedchem.0c01547","article-title":"Structure-activity relationship and bioactivity of short analogues of ELABELA as agonists of the apelin receptor","volume":"64","author":"Tran","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib77","doi-asserted-by":"crossref","first-page":"H2540","DOI":"10.1152\/ajpheart.00046.2008","article-title":"Apelin decreases the SR Ca2+ content but enhances the amplitude of [Ca2+]i transient and contractions during twitches in isolated rat cardiac myocytes","volume":"294","author":"Wang","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib78","doi-asserted-by":"crossref","first-page":"e2997","DOI":"10.1002\/dmrr.2997","article-title":"Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice","volume":"34","author":"Wang","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.ejphar.2023.175727_bib79","doi-asserted-by":"crossref","first-page":"633","DOI":"10.33549\/physiolres.931928","article-title":"Animal models in the study of exercise-induced cardiac hypertrophy","volume":"59","author":"Wang","year":"2010","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ejphar.2023.175727_bib80","first-page":"1","article-title":"A first-in-human study of AMG 986, a novel apelin receptor agonist, in healthy subjects and heart failure patients","author":"Winkle","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejphar.2023.175727_bib81","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/dna.2016.3574","article-title":"Caveolin-1-autophagy pathway mediated cardiomyocyte hypertrophy induced by apelin-13","volume":"36","author":"Wu","year":"2017","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ejphar.2023.175727_bib82","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijcard.2019.04.089","article-title":"Recombinant Fc-Elabela fusion protein has extended plasma half-life andmitigates post-infarct heart dysfunction in rats","volume":"292","author":"Xi","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib83","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/abbs\/gmv111","article-title":"Apelin-13 promotes cardiomyocyte hypertrophy via PI3K-Akt-ERK1\/2-p70S6K and PI3K-induced autophagy","volume":"47","author":"Xie","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejphar.2023.175727_bib84","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/abbs\/gmu046","article-title":"A static pressure sensitive receptor APJ promote H9c2 cardiomyocyte hypertrophy via PI3K-autophagy pathway","volume":"46","author":"Xie","year":"2014","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ejphar.2023.175727_bib85","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/aps.2017.97","article-title":"The endoplasmic reticulum stress-autophagy pathway is involved in apelin-13-induced cardiomyocyte hypertrophy in vitro","volume":"38","author":"Xie","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2023.175727_bib86","article-title":"Significance and determinants of plasma apelin in patients with obstructive hypertrophic cardiomyopathy","volume":"9","author":"Yang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib87","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCULATIONAHA.116.023218","article-title":"Elabela\/Toddler is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension","volume":"135","author":"Yang","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2023.175727_bib88","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bph.14603","article-title":"A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension","volume":"176","author":"Yang","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175727_bib89","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/jcp.30685","article-title":"Apelin-13\/APJ induces cardiomyocyte hypertrophy by activating the Pannexin-1\/P2X7 axis and FAM134B-dependent reticulophagy","volume":"237","author":"Yang","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2023.175727_bib90","first-page":"447","article-title":"Apelin-13 promotes cell proliferation in the H9c2 cardiomyoblast cell line by triggering extracellular signal-regulated kinase 1\/2 and protein kinase B phosphorylation","volume":"17","author":"Yin","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2023.175727_bib91","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41594-022-00797-5","article-title":"Structural insight into apelin receptor-G protein stoichiometry","volume":"29","author":"Yue","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejphar.2023.175727_bib92","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/jcmm.12208","article-title":"Apelin inhibits the proliferation and migration of rat PASMCs via the activation of PI3K\/Akt\/mTOR signal and the inhibition of autophagy under hypoxia","volume":"18","author":"Zhang","year":"2014","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib93","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.3892\/mmr.2015.3866","article-title":"Apelin\/APJ signaling promotes hypoxia-induced proliferation of endothelial progenitor cells via phosphoinositide-3 kinase\/Akt signaling","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2023.175727_bib94","article-title":"FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175727_bib95","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1016\/j.bmc.2014.04.001","article-title":"Identifying structural determinants of potency for analogs of apelin-13: integration of C-terminal truncation with structure-activity","volume":"22","author":"Zhang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175727_bib96","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2022.01.020","article-title":"Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6\/STAT3\/GPX4 signaling","volume":"181","author":"Zhang","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2023.175727_bib97","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/HYPERTENSIONAHA.117.10156","article-title":"Apelin is a negative regulator of angiotensin II-mediated adverse myocardial remodeling and dysfunction","volume":"70","author":"Zhang","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2023.175727_bib98","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.bbadis.2016.11.007","article-title":"Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases","volume":"1863","author":"Zhong","year":"2017","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2023.175727_bib99","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200040","article-title":"Apelin-13 alleviated cardiac fibrosis via inhibiting the PI3K\/Akt pathway to attenuate oxidative stress in rats with myocardial infarction-induced heart failure","volume":"40","author":"Zhong","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejphar.2023.175727_bib100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0042-6822(03)00185-5","article-title":"Binding of ALX40-4C to APJ, a CNS-based receptor, inhibits its utilization as a co-receptor by HIV-1","volume":"312","author":"Zhou","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.ejphar.2023.175727_bib101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2003.08.026","article-title":"The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity","volume":"317","author":"Zhou","year":"2003","journal-title":"Virology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923002388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923002388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:43:30Z","timestamp":1736347410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923002388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":101,"alternative-id":["S0014299923002388"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175727","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apelin\/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175727"}}